Patents by Inventor Manmohan R. Leleti

Manmohan R. Leleti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AZAINDAZOLE COMPOUNDS AND METHODS OF USE
    Publication number: 20180250293
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: November 21, 2017
    Publication date: September 6, 2018
    Inventors: Penglie ZHANG, Andrew M.K. PENNELL, John J. Kim WRIGHT, Wei CHEN, Manmohan R. LELETI, Yandong LI, Lianfa LI, Yuan XU, Mark M. GLEASON, Yibin ZENG, Kevin Lloyd GREENMAN
  • AZAINDAZOLE COMPOUNDS AND METHODS OF USE
    Publication number: 20160296517
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: February 23, 2016
    Publication date: October 13, 2016
    Inventors: Penglie ZHANG, Andrew M. K. Pennell, John J. Kim Wright, Wei Chen, Manmohan R. Leleti, Yandong Li, Lianfa Li, Yuan Xu, Mark M. Gleason, Yibin Zeng, Kevin Lloyd Greenman
  • Azaindazole compounds and methods of use
    Patent number: 9296740
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: March 29, 2016
    Assignee: ChemoCentryx, Inc.
    Inventors: Penglie Zhang, Andrew M. K. Pennell, John J. Kim Wright, Wei Chen, Manmohan R. Leleti, Yandong Li, Lianfa Li, Yuan Xu, Mark M. Gleason, Yibin Zeng, Kevin Lloyd Greenman
  • Pyrrolidinone carboxamide derivatives
    Patent number: 8716494
    Abstract: Pyrrolidinone carboxamide compounds are provided that are useful for inhibiting the binding of ligands to the ChemR23 receptor.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: May 6, 2014
    Assignee: ChemoCentryx, Inc.
    Inventors: Trevor T. Charvat, Hiufung Chu, Antoni Krasinski, Christopher W. Lange, Manmohan R. Leleti, Jay P. Powers, Sreenivas Punna, Timothy J. Sullivan, Solomon Ungashe
  • AZAINDAZOLE COMPOUNDS AND METHODS OF USE
    Publication number: 20130338157
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: February 22, 2013
    Publication date: December 19, 2013
    Applicant: Chemocentryx, Inc.
    Inventors: Penglie Zhang, Andrew M.K. Pennell, John J. Kim Wright, Wei Chen, Manmohan R. Leleti, Yandong Li, Lianfa Li, Yuan Xu, Mark M. Gleason, Yibin Zeng, Kevin Lloyd Greenman
  • Azaindazole compounds and methods of use
    Patent number: 8383630
    Abstract: Provided are methods for the treatment of rheumatoid arthritis using compounds of formula Ia and Ib: or a pharmaceutically acceptable salt, hydrate or N-oxide thereof.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: February 26, 2013
    Assignee: Chemocentryx, Inc.
    Inventors: Penglie Zhang, Andrew M. K. Pennell, John J. Kim Wright, Wei Chen, Manmohan R. Leleti, Yandong Li, Lianfa Li, Yuan Xu
  • AZAINDAZOLE COMPOUNDS AND METHODS OF USE
    Publication number: 20110098308
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: July 1, 2010
    Publication date: April 28, 2011
    Applicant: Chemocentryx, Inc.
    Inventors: Penglie Zhang, Andrew M.K. Pennell, John J. Kim Wright, Wei Chen, Manmohan R. Leleti, Yandong Li, Lianfa Li, Yuan Xu, Mark M. Gleason, Yibin Zeng, Kevin Lloyd Greenman
  • Azaindazole compounds and methods of use
    Patent number: 7777035
    Abstract: Methods are provided for the synthesis of 1-[4-(substituted phenyl)-piperazin-1-yl ] -2- [3-(1H-imidazol-2-yl)-pyrazolo [3,4-b]pyridin-1-yl]-ethanone compounds via construction of the imidazole portion onto the corresponding aldehyde or nitrile compounds.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: August 17, 2010
    Assignee: Chemocentryx, Inc.
    Inventors: Penglie Zhang, Andrew M. K. Pennell, John J. Kim Wright, Wei Chen, Manmohan R. Leleti, Yandong Li, Lianfa Li, Yuan Xu, Mark M. Gleason, Yibin Zeng, Kevin Lloyd Greenman
  • AZAINDAZOLE COMPOUNDS AND METHODS OF USE
    Publication number: 20090252779
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: April 3, 2009
    Publication date: October 8, 2009
    Applicant: ChemoCentryx, Inc.
    Inventors: Penglie Zhang, Andrew M.K. Pennell, John J. Kim Wright, Wei Chen, Manmohan R. Leleti, Yandong Li, Lianfa Li, Yuan Xu
  • Azaindazole compounds and methods of use
    Patent number: 7524845
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Grant
    Filed: June 22, 2006
    Date of Patent: April 28, 2009
    Assignee: ChemoCentryx, Inc.
    Inventors: Penglie Zhang, Andrew M. K. Pennell, John J. Kim Wright, Wei Chen, Manmohan R. Leleti, Yandong Li, Lianfa Li, Yuan Xu